Leading Research. Promising Drug Trials.
Over the past 30 years, New York Oncology Hematology patients have participated in clinical drug trials leading to FDA approval of 59 new cancer therapies. With the largest, most comprehensive clinical research operation in the region, NYOH is constantly offering eligible patients opportunities to join new trials.
About Clinical Research
Clinical trials are human research studies, conducted with volunteers who participate in the testing of new therapies. The purpose is finding new, more effective cancer treatment. NYOH is the largest organization in the area that participates in Phase I/II and III trials, including those for all major solid tumor types, hematologic malignancies and supportive care.
Our Clinical Research Mission
NYOH is committed to delivering high quality, ethically conducted, world class clinical research trials and superior research support services to promote the scientific advancement of cancer care as we offer our patients access to breakthrough treatments close to home.
The NYOH Clinical Research Program
Through our affiliation with The US Oncology Network, one of the largest and most reputable community-based research networks in the world, NYOH has access to some of the most promising new trials being offered. We also participate in National Cancer Institute (NCI) sponsored research.
At New York Oncology Hematology, we are proud of our role in the research and development of vital new cancer therapies. And we are deeply committed to bringing clinical trials to our community, offering patients an opportunity to help shape the future of cancer treatment, while benefitting from the very latest in clinical trials.
Over the past two decades, more than 3,000 NYOH patients have participated in clinical drug trials leading to FDA approval of 50 new cancer therapies:
To learn more about a study or to refer an eligible patient, please contact: